Germany's Apceth Biopharma gets contract to manufacture EU-approved Zynteglo

apceth Biopharma
Germany CDMO Apceth Biopharma has won the contract to produce Bluebird Bio’s recently EU-approved Zynteglo. (apceth)

Germany’s Apceth Biopharma, a CDMO focused on cell and gene therapeutics, has won the contract to produce Bluebird Bio’s recently EU-approved Zynteglo.

The European Commission granted conditional marketing authorization Monday for Zynteglo, which is a gene therapy designed to treat transfusion-dependent β-thalassemia (TDT).

Zynteglo adds functional copies of an altered form of the β-globin gene into TDT patients’ own blood stem cells. The inserted genes then produce hemoglobin at normal levels, reducing or eliminating the need for the frequent blood transfusions that TDT patients generally receive.

Free Amazon Webinar

Performing end to end real-world evidence generation in the cloud with traceability and transparency- a Sanofi journey

In this webinar you will hear about Sanofi’s journey and experience in building an industrialized big data & analytics platform in the cloud that handles billions of rows of RWD data with complete data traceability, security, and supports both traditional and advanced analytics for day to day evidence generation (RWE).

“We are proud to be the commercial manufacturing partner of Bluebird Bio and to be part of bringing this life-changing therapy to TDT patients in Europe,” Christine Guenther, M.D., Apceth’s chief excecutive, said in a statement. “Being one of the very few companies worldwide to manufacture a cell-based gene therapy for commercial use marks a milestone for our company.”

Bluebird has said it expects to file for FDA approval of Zynteglo by the end of the year.

In April, Hitachi Chemical completed its $86.8 million acquisition of Apceth in a deal that gave the Japanese conglomerate two manufacturing sites in Munich with 6,458 square feet of cleanroom space.

Suggested Articles

Nearly four decades after it was approved, the FDA has ordered that heartburn drug Zantac and its generics be removed from the market.

Pfizer's 1.1-million-square-foot sterile injectables plant in Visakhapatnam has been criticized by the FDA for poor quality testing.

Amidst a gung-ho shift to oncology, Daiichi is also fleshing out its gene therapy capacity with a $200 million licensing deal with Ultragenyx.